Marie-Louise Vachon
Chercheuse associée
Axe Maladies infectieuses et immunitaires
Dernières nouvelles
Publications
Voir tout-
article Imsirovic H, Macphail G, Conway B, Fraser C, Borgia S, Smyth D, Wong A, Vachon ML, Webster D, Liu H, Feld J, Lee S, Cooper C and
Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis
J Viral Hepat 31 (11), 2024.
-
article Marathe G, Moodie EEM, Brouillette MJ, Lanièce Delaunay C, Cox J, Martel-Laferrière V, Gill J, Cooper C, Pick N, Vachon ML, Vachon ML, Walmsley S, Klein MB and
Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada
Clin Infect Dis 76 (3), 2023.
-
article Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A and
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
N Engl J Med 388 (16), 2023.
Projets
- Surveillance des réponses immunitaires au vaccin contre la COVID-19 chez les personnes vivant avec le VIH-1, du 2021-12-01 au 2025-03-31
- A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV, du 2022-10-01 au 2027-09-30
- A Phase 2,Multicenter,Randomized,Double-Blind,Placebo-controlled Study to Evaluate Efficacy,Safety,Tolerability,and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral [...], du 2024-03-28 au 2029-12-25
- Optimiser le dépistage des populations vulnérables par goutte de sang séché, du 2022-01-15 au 2024-10-15
- After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada, du 2022-10-01 au 2023-03-31
- Optimization of a live microneutralization assay to evaluate antibody levels against mpox in vaccinated or infected individuals in Quebec, du 2023-04-24 au 2024-04-23